Status:
COMPLETED
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
Lead Sponsor:
Pfizer
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjuncti...
Eligibility Criteria
Inclusion
- Psychiatrically stable subjects with schizophrenia.
- Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
- Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.
Exclusion
- History of seizures or of a condition with risk of seizures.
- Subjects who have had electroconvulsive therapy within the 6 months prior to randomization.
- Pregnant or nursing females, and females of child bearing potential.
Key Trial Info
Start Date :
March 6 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 17 2013
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT01829048
Start Date
March 6 2013
End Date
October 17 2013
Last Update
August 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
California Clinical Trials Medical Group
Glendale, California, United States, 91206